Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification

Chao-Ling Wan^#^{1

2}, Yu-Qing Liu^#³, Fang-Tong Liu^#^{1

2}, Yuan-Hong Huang^{1

2}, Han-Yu Cao^{1

2}, Si-Man Huang^{1

2}, Kai-Wen Tan^{1

2}, Shuai-Shuai Ge^{1

2}, Miao Wang^{1

2}, Mei-Jing Liu^{1

2}, Zi-Hao Wang^{1

2}, Zheng Li^{4

5}, Sheng-Li Xue^{6

7}, Hai-Ping Dai^{8

9}

Affiliations

¹ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
² Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
³ Changshu Hospital Affiliated to Soochow University, Changshu No.1 People's Hospital, Changshu, Jiangsu Province, China.
⁴ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. lzheng@suda.edu.cn.
⁵ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. lzheng@suda.edu.cn.
⁶ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. slxue@suda.edu.cn.
⁷ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. slxue@suda.edu.cn.
⁸ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. daihaiping8@126.com.
⁹ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. daihaiping8@126.com.

^# Contributed equally.

PMID: 39179571
PMCID: PMC11344036
DOI: 10.1038/s41408-024-01130-7

Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification

Chao-Ling Wan et al. Blood Cancer J. 2024.

. 2024 Aug 23;14(1):144.

doi: 10.1038/s41408-024-01130-7.

Authors

Affiliations

¹ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
² Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
³ Changshu Hospital Affiliated to Soochow University, Changshu No.1 People's Hospital, Changshu, Jiangsu Province, China.
⁴ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. lzheng@suda.edu.cn.
⁵ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. lzheng@suda.edu.cn.
⁶ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. slxue@suda.edu.cn.
⁷ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. slxue@suda.edu.cn.
⁸ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. daihaiping8@126.com.
⁹ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. daihaiping8@126.com.

^# Contributed equally.

PMID: 39179571
PMCID: PMC11344036
DOI: 10.1038/s41408-024-01130-7

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

**Fig. 1. Responses and survival analysis of matched cohorts.**
A Univariable and multivariable logistic regression overall response analysis. B, C OS and EFS analysis of the overall 7 + 3 and VEN + HMA cohorts. D, E OS and EFS analysis in patients without allo-HSCT per 7 + 3 or VEN + HMA treatment. F Univariable and multivariable Cox regression survival analysis. (CI confidence interval, OR odds ratio, EFS event-free survival, OS overall survival, VEN + HMA, venetoclax plus hypomethylating agents, NR not reached, UVA univariable analysis, MVA multivariable analysis, Allo-HSCT allogenetic hematopoietic stem cell transplantation, HR hazard ratio).

See this image and copyright information in PMC

References

1. Tsai XC, Sun KJ, Lo MY, Tien FM, Kuo YY, Tseng MH, et al. Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML. Blood Cancer J. 2023;13:4. 10.1038/s41408-022-00774-7 - DOI - PMC - PubMed
1. Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:502–26. 10.1002/ajh.26822 - DOI - PubMed
1. Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, et al. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv. 2021;5:2173–83. 10.1182/bloodadvances.2020004173 - DOI - PMC - PubMed
1. Lu J, Xue S, Wang Y, Dai HP, He X, Hu X, et al. Comparing the efficacy and safety of venetoclax combined with decitabine versus conventional chemotherapy as induction therapy for young adults with newly diagnosed acute myeloid leukemia - interim analysis of a multicenter, randomized, phase 2b trial. Blood. 2023;142:970.10.1182/blood-2023-181347 - DOI
1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28. 10.1182/blood.2022015850 - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification

Affiliations

Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification

Authors

Affiliations

Conflict of interest statement

Figures

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical